Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (4): 1085-1086.doi: 10.4103/NRR.NRR-D-24-00131

Previous Articles     Next Articles

New glucocerebrosidase antibodies can advance research in the field of neurodegenerative disorders

Charis Ma# , Krystyna Rytel# , Yu Chen, Ellen Sidransky*   

  1. Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
  • Online:2025-04-15 Published:2024-07-01
  • Contact: Ellen Sidransky, MD, sidranse@nih.gov.

PDF

19

Abstract: In medical research, there are times when the introduction of a new tool can launch scientific discovery in new directions. While antibody development may be considered mundane, in the field of glucocerebrosidase (GCase) research, the dearth of validated antibodies for different applications has impeded progress in studies of disease pathogenesis and therapeutic development. The recent introduction of new, rigorously evaluated antibodies can now propel research into the link between glucocerebrosidase and Parkinson’s disease (PD) as well as aspects of the pathobiology of Gaucher disease (Jong et al., 2024).